Comparing the efficacy and safety of Tirzepatide with Semaglutide in patients with overweight or obesity: a Meta-analysis

doi:10.3877/cma.j.issn.2095-9605.2025.02.006

Abstract

Abstract:

Objective

Evaluating the efficacy and safety of tirzepatide compared with semaglutide in patients with overweight or obesity by a meta-analysis.

Methods

Medline, Pubmed, Embase, Web of Science, Cochrane Libarary, CNKI, Wanfang and CMJD were searched for studies comparing tirzepatide with semaglutide in patients with overweight or obesity. The quality of including studies was assessed by methodological index for non-randomized studies (MINORS). Stata 14.0 was used for meta-analysis.

Results

3 studies (18611 individuals) were analysed. No statistical difference was found between the two groups in total weight reduction (%) (MD=-4.26%, 95%CI: -8.63%~0.10%). Patients receiving tirzepatide had a significantly higher proportion of weight loss ≥5%, ≥10% and ≥15% compared with semaglutide (92% vs. 72%, 64% vs. 45%, 45% vs. 23%). There was no statistical difference between the two medications in the occurrence of total adverse events (RR 1.00, 95%CI: 0.89~1.13).

Conclusions

Our results suggest the use of tirzepatide is better than that of semaglutide in patients with overweight or obesity which lead a significant weight reduction with a low occurrence of adverse reactions and can be a new option for the treatment of obesity.

Key words: Tirzepatide, Semaglutide, Overweight, Obesity, Meta-analysis

Shibo Bian, Yiqiao Zhang, Meng Zhang, Yang Liu. Comparing the efficacy and safety of Tirzepatide with Semaglutide in patients with overweight or obesity: a Meta-analysis[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2025, 11(02): 121-128.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2025.02.006

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2025/V11/I02/121

Figures/Tables 7

References 27

[1]	NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults [J]. Lancet, 2024, 403(10431): 1027-1050.
[2]	Lim SS, Vos T, Flaxman AD, Danaei G, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [J]. Lancet, 2012, 380(9859): 2224-2260.
[3]	Raisi-Estabragh Z, Kobo O, Mieres JH, et al. Racial disparities in obesity-related cardiovascular mortality in the united states: temporal trends from 1999 to 2020 [J]. J Am Heart Assoc, 2023, 12(18): e028409.
[4]	Lin C, Yeong TJJ, Lim WH, et al. Comparison of mechanistic pathways of bariatric surgery in patients with diabetes mellitus: A Bayesian network meta-analysis [J]. Obesity (Silver Spring), 2022, 30(7): 1380-1390.
[5]	Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials [J]. Lancet, 2022, 399(10321): 259-269.
[6]	Alkhezi OS, Alahmed AA, Alfayez OM, et al. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials [J]. Obes Rev, 2023, 24(3): e13543.
[7]	Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial [J]. Jama, 2022, 327(2): 138-150.
[8]	Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials[J]. Diabetes Ther, 2021, 12(1): 143-157.
[9]	Regmi A, Aihara E, Christe ME, et al. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor [J]. Cell Metab, 2024, 36(7): 1534-1549. e1537.
[10]	Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes [J]. N Engl J Med, 2021, 385(6): 503-515.
[11]	Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis [J]. Diabetologia, 2022, 65(8): 1251-1261.
[12]	Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity [J]. JAMA Intern Med, 2024. Online ahead of print.
[13]	Zakaria H, Alshehhi S, Caccelli M, et al. Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study [J]. Metabol Open, 2024, 22: 100283.
[14]	Jamal M, Alhashemi M, Dsouza C, et al. Semaglutide and Tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study[J]. Obes Surg, 2024, 34(4): 1324-1332.
[15]	astreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med, 2022, 387(3): 205-216.
[16]	Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over [J]. Curr Obes Rep, 2017, 6(2): 187-194.
[17]	Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial [J]. Nat Med, 2022, 28(10): 2083-2091.
[18]	Gudzune KA, Kushner RF. Medications for obesity: A review[J]. Jama, 2024, 332(7): 571-584.
[19]	Ding Y, Shi Y, Guan R, et al. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis [J]. Pharmacol Res, 2024, 199: 107031.
[20]	Le MH, Yeo YH, Zou B, et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach [J]. Clin Mol Hepatol, 2022, 28(4): 841-850.
[21]	Gastaldelli A, Cusi K, Fernández Landó L, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial [J]. Lancet Diabetes Endocrinol, 2022, 10(6): 393-406.
[22]	le Roux CW, Hankosky ER, Wang D, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison [J]. Diabetes Obes Metab, 2023, 25(9): 2626-2633.
[23]	Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes [J]. Diabetes Care, 2023, 46(5): 998-1004.
[24]	Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial [J]. Lancet Diabetes Endocrinol, 2022, 10(6): 418-429.
[25]	Samms RJ, Sloop KW, Gribble FM, et al. GIPR Function in the central nervous system: implications and novel perspectives for gip-based therapies in treating metabolic disorders [J]. Diabetes, 2021, 70(9): 1938-1944.
[26]	Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension [J]. Diabetes Obes Metab, 2022, 24(8): 1553-1564.
[27]	Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial [J]. Jama, 2024, 331(1): 38-48.

作者	年份	研究类型	总例数	平均年龄（年）	替尔泊肽组年龄（年）	司美格鲁肽组年龄（年）	替尔泊肽组性别比（男:女）	司美格鲁肽组性别比（男:女）	替尔泊肽组体重（kg）	司美格鲁肽组体重（kg）	替尔泊肽组BMI（kg/m²）	司美格鲁肽组BMI（kg/m²）	糖尿病（%）	用药剂量	结局指标	干预时间（月）
Rodriguez等^[12]	2024	回顾性研究	18385	52.0±12.9	51.9±12.7	52.0±13.2	2709: 6484	2707: 6486	110±25.7	110±25.8	39.0±8.08	39.1±8.09	52.0	替尔泊肽5 mg 司美格鲁肽0.5 mg	体重变化、药物不良反应	12个月
Zakaria等^[13]	2024	回顾性研究	111	43.1±9.9	未详细分组		44: 67（总性别比，未详细分组）		95.44±20.92（总基线体重，未详细分组）		<30，31；>30,80（未详细分组）		22.9	替尔泊肽5/7.5/10 mg 司美格鲁肽1.0 mg	体重变化、代谢疾病改善情况	3个月
Jamal等^[14]	2024	回顾性研究	115	38.1±10.4	40.2±10.5	38.1±10.3	8: 37	14: 56	100.2±28.5	90.1±19.4	36.9±7.1	33.9±6.0	1.7	替尔泊肽<10 mg,>10 mg 司美格鲁肽<1.0 mg,>1.0 mg	体重变化、药物不良反应	6个月

作者	年份	研究类型	总例数	平均年龄（年）	替尔泊肽组年龄（年）	司美格鲁肽组年龄（年）	替尔泊肽组性别比（男:女）	司美格鲁肽组性别比（男:女）	替尔泊肽组体重（kg）	司美格鲁肽组体重（kg）	替尔泊肽组BMI（kg/m²）	司美格鲁肽组BMI（kg/m²）	糖尿病（%）	用药剂量	结局指标	干预时间（月）
Rodriguez等^[12]	2024	回顾性研究	18385	52.0±12.9	51.9±12.7	52.0±13.2	2709: 6484	2707: 6486	110±25.7	110±25.8	39.0±8.08	39.1±8.09	52.0	替尔泊肽5 mg 司美格鲁肽0.5 mg	体重变化、药物不良反应	12个月
Zakaria等^[13]	2024	回顾性研究	111	43.1±9.9	未详细分组		44: 67（总性别比，未详细分组）		95.44±20.92（总基线体重，未详细分组）		<30，31；>30,80（未详细分组）		22.9	替尔泊肽5/7.5/10 mg 司美格鲁肽1.0 mg	体重变化、代谢疾病改善情况	3个月
Jamal等^[14]	2024	回顾性研究	115	38.1±10.4	40.2±10.5	38.1±10.3	8: 37	14: 56	100.2±28.5	90.1±19.4	36.9±7.1	33.9±6.0	1.7	替尔泊肽<10 mg,>10 mg 司美格鲁肽<1.0 mg,>1.0 mg	体重变化、药物不良反应	6个月

文献	研究目的明确	纳入对象连贯	计划数据收集	终点结局能否反应研究目的	终点结局评价的客观性	随访时间是否充足	失访率低于5%	总分
Rodriguez等^[12]	2	2	2	2	2	2	2	14
Zakaria等^[13]	2	2	2	2	2	2	2	14
Jamal等^[14]	2	2	2	2	2	2	1	13

文献	研究目的明确	纳入对象连贯	计划数据收集	终点结局能否反应研究目的	终点结局评价的客观性	随访时间是否充足	失访率低于5%	总分
Rodriguez等^[12]	2	2	2	2	2	2	2	14
Zakaria等^[13]	2	2	2	2	2	2	2	14
Jamal等^[14]	2	2	2	2	2	2	1	13

Please choose a citation manager

Content to export